Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICOTEL: Cobimetinib + Atezolizumab (+ Vemurafenib) in CNS Melanoma
NCT03625141Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of atezolizumab, cobimetinib in melanoma, sponsored by Roche. Started Dec 2018; status: completed.
02
Drugs
atezolizumabcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03625141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625141.